CMS considers adverse events disclosures
This article was originally published in The Gray Sheet
Medicare agency is evaluating whether it should post the incidences of hospital-acquired conditions on its Hospital Compare Web site, according to Jan. 5 memo from the HHS Office of Inspector General. "CMS contracted for the evaluation in September 2009, and will determine the extent of disclosure after findings are known," OIG said. CMS may release results from the evaluation focused on the Medicare agency's hospital-acquired conditions policy, its effects on Medicare reimbursement, utilization, quality, patient safety and unintended consequences. Because Medicare claims data lack information on causes of adverse events or prevention strategies, the agency may seek to combine it with data from other systems. The OIG memo cautions that some stakeholders are worried that public disclosure of adverse events can undermine patient privacy
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.